A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee
Status:
Terminated
Trial end date:
2020-10-29
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the efficacy of REGN5069 compared to
placebo in patients with pain due to radiographically-confirmed OA of the knee who have a
history of inadequate joint pain relief or intolerance to current analgesic therapy.
The secondary objectives of the study are:
- To characterize the concentrations of functional REGN5069 in serum over time when
patients are treated for up to 12 weeks
- To assess the safety and tolerability of REGN5069 compared with placebo when patients
are treated for up to 12 weeks
- To measure levels of anti-drug antibodies (ADAs) against REGN5069 following multiple IV
administrations